Background: A new formulation of olanzapine available for terminally ill patients is needed. Rectal administration\nusing suppositories is an alternative for patients for whom administration via the oral route is not feasible. In the\npresent study, we prepared olanzapine suppositories, and confirmed using pharmaceutical tests. Furthermore, we\ndemonstrated the efficacy and safety of olanzapine suppositories in terminally ill patients.\nMethods: We prepared olanzapine suppositories using bases consisting of different compositions of Witepsol H-15,\nWitepsol S-55, and Witepsol E-75. The suppository release test was performed, and the olanzapine suppository with\nthe best dissolution rate was selected. The suppository was assessed using the content uniformity test, content test\nin suppositories, hardness test, stability test, and clinical efficacy and safety.\nResults: The dissolution rate at 360 min of olanzapine suppositories with Witepsol H-15 was the best (77.0 �± 3.3 %).\nThe suppositories prepared had a uniform weight (2.47 �± 0.02 g) and content (2.11 �± 0.07 mg). The power required\nto break suppositories was 7.96 �± 0.55 kgf. When olanzapine suppositories were stored with protection from light,\ntheir contents were maintained regardless of whether the temperature was at 4 �°C or room temperature. The\nnumbers of patients administered 2.5 mg, 5 mg, and 10 mg of olanzapine suppositories were 4, 19, and 1. The\npercentages of patients with delirium or nausea and vomiting cured with olanzapine suppositories were 82 and\n57 %, respectively.\nConclusion: We suggest that olanzapine suppositories prepared in the hospital by pharmacists will improve the\nquality of life of terminally ill patients.
Loading....